BIT Companies and DRG Diagnostics Unveil First Hybrid Analyzer
BIT Companies and DRG Diagnostics GmbH have partnered to create the first hybrid analyzer - a fully-automated, random-access analyzer for immunoassays and clinical chemistry.
Wed Jun 27 2012
Schwalbach, Germany (PRWEB) June 27, 2012
BIT Companies, OEM manufacturer of in-vitro diagnostic clinical and hematology instrumentation, has partnered with DRG Diagnostics to launch a revolutionary new product – the DRG:HYBRID XL Analyzer, a fully-automated and integrated random-access analyzer for immunoassays and clinical chemistry. This innovative and unique technology allows, for the first time, the simultaneous measurement of immunoassays and clinical chemistry parameters including turbidimetric tests in one sample.
The DRG:HYBRID XL fully-automated analyzer is ideal for small and medium-sized labs. However, it is also suitable for high-workload laboratories performing special routine and niche parameters automatically. The analyzer is flexible enough to measure 40 different tests from one sample or just one or two tests from 20 samples. Additionally, the unique concept of the DRG:HYBRID XL allows each user to combine individual diagnostic panels from immunoassays and clinical chemistry. BIT Companies provided the hybrid technology concept, working in cooperation with designers to develop the core product idea and industrial design through to engineering, prototype, validation and final production. We are excited about the full product launch of the HYBRID XL Analyzer by DRG.
BIT Companies will feature this new technology at the 2012 annual meeting of the American Association of Clinical Chemistry (Booth #937) in Los Angeles, CA, USA July 15-19.